| Literature DB >> 31318902 |
Fabian Frost1, Lena J Storck1,2, Tim Kacprowski3,4, Simone Gärtner1, Malte Rühlemann5, Corinna Bang5, Andre Franke5, Uwe Völker3, Ali A Aghdassi1, Antje Steveling1, Julia Mayerle1,6, Frank U Weiss1, Georg Homuth3, Markus M Lerch1.
Abstract
The global obesity epidemic constitutes a major cause of morbidity and mortality challenging public health care systems worldwide. Thus, a better understanding of its pathophysiology and the development of novel therapeutic options are urgently needed. Recently, alterations of the intestinal microbiome in the obese have been discussed as a promoting factor in the pathophysiology of obesity and as a contributing factor to related diseases such as type 2 diabetes and metabolic syndrome. The present pilot study investigated the effect of a structured weight loss program on fecal microbiota in obese type 2 diabetics. Twelve study subjects received a low-calorie formula diet for six weeks, followed by a nine week food reintroduction and stabilization period. Fecal microbiota were determined by 16S rRNA gene sequencing of stool samples at baseline, after six weeks and at the end of the study after fifteen weeks. All study subjects lost weight continuously throughout the program. Changes in fecal microbiota were most pronounced after six weeks of low-calorie formula diet, but reverted partially until the end of the study. However, the gut microbiota phylogenetic diversity increased persistently. The abundance of Collinsella, which has previously been associated with atherosclerosis, decreased significantly during the weight loss program. This study underlines the impact of dietary changes on the intestinal microbiome and further demonstrates the beneficial effects of weight loss on gut microbiota. Trial registration: ClinicalTrials.gov NCT02970838.Entities:
Mesh:
Year: 2019 PMID: 31318902 PMCID: PMC6638920 DOI: 10.1371/journal.pone.0219489
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Laboratory evaluation of metabolic parameters at different study time points.
| Baseline (0 weeks) | 6 weeks | 15 weeks | p value | |
|---|---|---|---|---|
| HbA1c | 6.6 (6.1–7.2) | - | 6.0 (5.4–6.4) | 0.003 |
| Fasting glucose (mmol/l) | 6.9 (6.2–8.3) | - | 5.8 (5.4–6.2) | 0.002 |
| Insulin | 154.3 (102.4–217.8) | - | 84.3 (53.1–99.8) | 0.002 |
| Total cholesterol (mmol/l) | 4.7 (4.5–5.8) | 4.5 (3.2–4.8) | 4.8 (4.0–4.8) | 0.016 |
| LDL | 2.7 (2.6–3.4) | 2.7 (1.9–3.2) | 2.9 (2.6–3.0) | 0.035 |
| HDL | 1.2 (0.9–1.4) | 1.0 (1.0–1.3) | 1.1 (1.0–1.3) | 0.234 |
| Triglycerides (mmol/l) | 1.6 (1.1–2.5) | 1.0 (0.9–1.6) | 1.5 (0.9–2.2) | 0.178 |
| Uric acid | 316.0 (282.8–356.2) | 250.5 (200.8–299.5) | 273.5 (249.5–354.2) | 0.024 |
Metabolic laboratory parameters of the twelve participants were evaluated at baseline (0 weeks), after the low-calorie formula diet (6 weeks) and after reintroduction of a regular diet (15 weeks). LDL: Low density lipoprotein. HDL: High density lipoprotein. Data are given as median (first to third quartiles). Wilcoxon signed-rank test and Friedman test were used for assessment of significance in case of two or three different time points, respectively.
# one participant was not fasting before the blood sample was obtained and therefore excluded from the analysis.
* indicates significant test result. All values were rounded to one decimal place.